Digirad Corporation Announces Appointment of Todd Clyde as Chief Executive Officer

Digirad Corporation today announced the appointment of Todd P. Clyde as president and chief executive officer. He replaces Mark Casner, 53, who resigned as president, chief executive officer and director of the company to pursue new business opportunities effective today. Clyde has been chief financial officer since November 2002 and will continue in that position [...]

HealthMarkets’ Subsidiary Introduces New Suite of Dental Insurance Products for Individuals of All Ages

HealthMarkets, Inc. (http://www.healthmarkets.com) announced today that its subsidiary, The MEGA Life and Health Insurance Company, has introduced a new suite of dental insurance products for individuals of all ages in 26 states.
HealthMarkets, through its insurance subsidiaries, is a provider of health insurance products for the self-employed, individuals and families and small businesses.
“Good dental health is [...]

S3 Investment Company Announces Release of October 2008 Newsletter

S3 Investment Company, Inc. and its wholly owned Redwood Capital subsidiary, which assists private Chinese companies in accessing the U.S. capital markets through reverse mergers into public companies, today released the October 2008 edition of its investor newsletter, which reviews the recently reported growth of Redwood Capital client Dalian Chuming, which now trades in the [...]

Initiation of Clinical Development Builds Upon Broad Potential Shown in Preclinical Studies

Infinity Pharmaceuticals, Inc. (NasdaqGM:INFI – News), an innovative cancer drug discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its oral Hedgehog signaling pathway inhibitor, IPI-926, in patients with advanced and/or metastatic solid tumors.
IPI-926 is a novel, proprietary inhibitor of the Hedgehog signaling pathway. It is a derivative [...]

Edwards Lifesciences’ New Transcatheter Heart Valve Data Demonstrate Positive Results

Edwards Lifesciences Corporation, the world leader in the science of heart valves, announced that new data from two studies of the Edwards SAPIEN transcatheter aortic heart valve with the RetroFlex transfemoral delivery system were presented today at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
The 30-day results from [...]

Boston Scientific Inc. announced comprehensive data from the TAXUS ATLAS clinical program

Boston Scientific Corporation today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, multi-center, single-arm, historically controlled trials, which evaluate the TAXUS® Liberte® Paclitaxel-Eluting Stent System in a variety of lesions and patient groups. The TAXUS Liberte Stent received U.S. Food and Drug Administration approval on Friday. Results from the [...]

Similarly Low Rates in Patients With Diabetes Compared to Non-Diabetics

Boston Scientific Corporation (NYSE: BSX – News) today announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1 and 2 registries, which are designed to confirm the performance of the TAXUS® Express2(TM) Paclitaxel-Eluting Coronary Stent System in real-world practice. The two-year pooled ARRIVE data showed that the TAXUS Stent reduced clinical [...]

Cell Therapeutics, Inc. announced to request a hearing with the NASDAQ Listing Qualifications Panel to present a plan for regaining compliance with NASDAQ Marketplace Rule

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Company intends to request a hearing with the NASDAQ Listing Qualifications Panel to present a plan for regaining compliance with NASDAQ Marketplace Rule 4450(b)(1)(A), which requires a minimum market value of listed securities of $50 million. CTI received a Staff Determination Letter from [...]

Allscripts Announces Per Share Amount of Special Cash Dividend of $5.23

Allscripts Healthcare Solutions, Inc. (”Allscripts”) (Nasdaq: MDRX – News), the leading provider of clinical software, connectivity and information solutions that physicians use to improve healthcare, announced today that the per share amount of the previously announced special cash dividend is $5.23 per share of common stock. The payment of the special cash dividend, which is [...]

Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent

Boston Scientific Corporation today announced it has received approval from the U.S. Food and Drug Administration to market its second-generation TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System. The Company plans to launch the TAXUS Liberte stent early next month in the United States, following completion of the introduction of its TAXUS® Expresss2(TM) Atom(TM) Paclitaxel-Eluting Coronary Stent [...]